Our Team
CORA Leadership
For three decades, our faculty have engaged in innovative research and clinical efforts to develop novel treatments for opioid-use disorder. Our work began with the seminal studies demonstrating buprenorphine (BUP) treatment efficacy, which contributed to its FDA approval.
Directors
Stacey Sigmon, PhD
Director, UVM CORA, Professor of Psychiatry, UVM Larner College of Medicine
Sarah Heil, PhD
Associate Director, UVM CORA, Professor of Psychology and Psychiatry, UVM Larner College of Medicine
Administration
Best Practices Core
Gail Rose, PhD
Director, Best Practices Core, Assistant Professor of Psychiatry, UVM Larner College of Medicine
Rick Rawson, PhD
Senior Advisor, Best Practices Core, Research Professor at UVM, Professor Emeritus at UCLA
Education & Outreach Core
Stephen Higgins, PhD
Co-Director, Education & Outreach Core, Vice Chair of Psychiatry, Director of Vermont Center on Behavior and Health
Surveillance & Evaluation Core
Andrea Villanti, PhD, MPH
Co-Director, Surveillance & Evaluation Core, Associate Professor of Psychiatry, UVM Larner College of Medicine
Clinician Advisory Board
Robert Althoff, MD, PhD
Associate Professor of Psychiatry, Pediatrics, and Psychological Sciences, UVM Larner College of Medicine
John Brooklyn, MD
Associate Clinical Professor of Family Medicine, Medicine and Psychiatry, UVM Larner College of Medicine
Brady Heward, MD
Co-Director of Clinical Affairs, Assistant Professor of Psychiatry, UVM Larner College of Medicine
Peter Jackson, MD
Co-Director of Clinical Affairs, Assistant Professor of Psychiatry, UVM Larner College of Medicine
Marjorie Meyer, MD
Professor of Obstetrics, Gynecology, and Reproductive Sciences, UVM Larner College of Medicine.
Strategic Partners
Mary Lindsey Smith, PhD, MSW
Senior Research Associate, University of Southern Maine, Cutler Institute for Health and Social Policy
This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $10,365,921 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS or the U.S. Government.